CORRECTION BY SOURCE: Corporate Update on Clinical Evaluation of MedMira’s Products
Correction: Extended clarification.HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide...
Pregnancy
Corporate Update on Clinical Evaluation of MedMira’s Products
HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide an update...
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset
Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize...
Study Unlocks New Hope in the Battle Against Male Infertility
A new study from UCLA and MicroGenDX shows that bacteria may be one of the factors holding back male fertilityORLANDO,...
Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
MIAMI, FL, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women
UC Davis Medical Center, a top regional and nationally ranked medical center, is the third academic center to participate in...
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
Renalys expected to initiate registrational study in the second quarter of 2024 to support potential approval of sparsentan for IgA...
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared...
Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024
MIAMI, FL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology
- University of Utah Hospital, Lori Gawron, M.D. of the Obstetrics and Gynecology (OB/GYN) Department, was an instrumental investigator in...
Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia
Financing was led by New Enterprise Associates (NEA) and closed with additional new investor Atlas Venture and continued investment by...
Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss
MIAMI, FL, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Top 10 Tummy Tuck Surgery Questions That Women Seek Answers To
NEWPORT BEACH, CA / ACCESSWIRE / January 4, 2024 / A tummy tuck, also known as abdominoplasty, is a cosmetic...
ALK to become sole manufacturer and distributor of skin antigen test for penicillin allergy
– PRE-PEN® (benzylpenicilloyl polylysine injection USP) is the only FDA-approved diagnostic skin test for the evaluation of penicillin allergyi,ii –...
Harrow Partners with Leading Healthcare Market Access Technology Platforms
Agreements Support the Upcoming Launch of VEVYE®NASHVILLE, Tenn.--(BUSINESS WIRE)--$HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that...
60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024
Investigational Review Board (IRB) approval has been granted for 60 Degrees Pharma’s double-blind, placebo-controlled study to investigate tafenoquine for treatment...
BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)
– Results published in JACI: In Practice show rapid and sustained reductions in HAE attacks and improved quality of life...
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine
- Stanford Medicine, a center with a long tradition of leadership in pioneering gynecological research and innovation, is the second...
Michigan Department of Health and Human Services Expands Philips Avent Pregnancy+ Program; Nearly 80% of Users Say App Has Helped Them Learn More About Locally Available Maternal Health Resources
Program reaches 12,000 Medicaid-eligible families Michigan-specific content viewed over 850,000 times in the first year Michigan expanding access to premium...
Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus Keytruda at Three Years
At a median planned follow-up of approximately three years, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence...